بدائل البحث:
nn decrease » _ decrease (توسيع البحث)
p decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
19 p » 19 _ (توسيع البحث), 19 a (توسيع البحث), 19 1 (توسيع البحث)
nn decrease » _ decrease (توسيع البحث)
p decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
19 p » 19 _ (توسيع البحث), 19 a (توسيع البحث), 19 1 (توسيع البحث)
-
781
-
782
-
783
-
784
-
785
-
786
-
787
-
788
Kv7 Channel Activators Flupirtine and ML213 Alleviate Neuropathic Pain Behavior in the Streptozotocin Rat Model of Diabetic Neuropathy
منشور في 2024"…Background & Objective: Chronic peripheral neuropathic pain (PNP) is a debilitating condition that is associated with many types of injury/diseases, including diabetes mellitus. …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
-
789
Dynamic stretching alone can impair slower velocity isokinetic performance of young male handball players for at least 24 hours
منشور في 2019"…Two-way repeated measures ANOVAs revealed that 1) both the SS and control conditions exhibited knee extensor 60.s -1 (SS:-10.3%; p = 0.04, Control: -8.7%; p = 0.07) and 300.s -1 (SS: -12.9%; p = 0.005, Control: -16.3%; p = 0.02) isokinetic deficits at post-test, 2) DS impaired knee flexor 60.s -1 isokinetic work and power-related measures at post-test (Work: -10.1%; p = 0.0006; Power: -19.1%; p = 0.08) and at 24-hours' post-test (Work: 9.9%; p = 0.023; Power: -9.6%; p = 0.01), 3) DS (12.07% and 10.47%) and SS (13.7% and 14.6%) enhanced knee flexor 300.s -1 isokinetic force and power-related measures compared to control. …"
احصل على النص الكامل
احصل على النص الكامل
-
790
-
791
-
792
-
793
-
794
-
795
-
796
-
797
-
798
-
799
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
منشور في 2023"…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
-
800